News and Articles on Ayurveda, Yoga, Kundalini and other Indian way of health and medicines.
Weinnovate Biosolutions was supported by CAWACH (Centre for Augmenting War with COVID-19 Health Crisis) 2020 grant from the National Science and Technology Entrepreneurship Development Board (NSTEDB) under the Department of Science and Technology (DST) and the project was incubated at Entrepreneurship Development Centre, Pune.
Council of Scientific & Industrial Research (CSIR), and Laxai Life Sciences Pvt. Ltd., Hyderabad, have been given the regulatory approval by the Drugs Controller General of India (DCGI) to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in the improvement of clinical outcomes during the treatment of COVID-19 patients. The partner CSIR institutes in this important clinical trial are the CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu.
The study conducted on 100 Chronic Low Back Pain (CLBP) patients of 50 years with 3 years of history of the disease. After systematic Yogic intervention of 4 weeks, Quantitative sensory testing (QST) showed increase in thresholds for cold pain and cold pain tolerance. Corticomotor excitability and flexibility improved significantly in the patients.
The Minister of State for Social Justice & Empowerment Shri Rattan Lal Katariahas said that in order to simplify the process of vaccination for the elderly and differently -abled, , the government has allowed the establishment of ‘near home’ vaccination centers for them. He was addressing aprogramme on the occasion of World Elder Abuse Awareness Day.
The Novavax trials conducted on 29,960 people in the US and Mexico have delivered results that equal the Pfizer and Moderna jabs and do better than Johnson and Johnson, but regulatory clearance appears distant as an overflowing vault of vaccines has diminished the need for emergency use approvals. Additional EUAs are not required under US law after enough dosages are available to meet domestic demands.
Council of Scientific and Industrial Research (CSIR)’s Lucknow-based constituent laboratory Central Drug Research Institute (CDRI) and Marc Laboratories Ltd, India have come together to develop a new safer drug for heart attack and stroke. They have signed the license agreement for developing drug for coronary and cerebral artery diseases.
Dr. Nikhil Narayan Bante, Lungs and TB Specialist, pointed out that a large number of COVID recovered patients are facing post-COVID-19 syndromes in the second wave of the pandemic. “Around 50%-70% of patients may experience minor or even major symptoms up to 3-6 months after recovering from COVID-19 and is observed more in those patients who had moderate or severe form of the infection”, he added
Indian Institute of Technology, Ropar has developed a device ‘Jivan Vayu’ which can be used as a substitute of CPAP machine. However, this is Nation’s first such device which functions even without electricity and is adapted to both kinds of oxygen generation units like O2 cylinders and oxygen pipelines in hospitals. These provisions are not available in otherwise existing CPAP machines.
Dozee, a Department of Biotechnology (DBT) and its PSU Biotechnology Industry Research Assistance Council (BIRAC) funded start-up offers ‘contact-free monitoring of the vital parameters of the patients on a normal bed. The innovation has already resulted in the upgrading of over 4,000 hospital beds for Step-Down ICUs across 35 districts in India. In the last months, Dozee has already served over 30,000 patients, saved over 65,000 nursing hours and prompted over 750 timely ICU transfers through its Early Warning System.
India’s first official beyond visual line of sight (BVLOS) medical drone delivery experiment is scheduled to begin this week in Gauribidanur, some 80km from Bengaluru.
